1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone
C34H29N3O3 — CID 127038395
Data last refreshed: (MolForge compound catalog, from PubChem)
About 1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone
1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone (PubChem CID 127038395) has the molecular formula C34H29N3O3 and a molecular weight of 527.62 g/mol. Its IUPAC name is 1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone.
Molecular Properties
| Compound Name | 1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone |
|---|---|
| PubChem CID | 127038395 |
| Molecular Formula | C34H29N3O3 |
| Molecular Weight | 527.62 g/mol |
| Exact Mass | 527.22 |
| IUPAC Name | 1-[3-[(1S,4R)-9-acetyl-1-(1-acetylindol-3-yl)-1,2,3,4-tetrahydrocarbazol-4-yl]indol-1-yl]ethanone |
| SMILES | CC(=O)n1cc([C@H]2CC[C@@H](c3cn(C(C)=O)c4ccccc34)c3c2c2ccccc2n3C(C)=O)c2ccccc21 |
| InChI | InChI=1S/C34H29N3O3/c1-20(38)35-18-28(23-10-4-7-13-30(23)35)25-16-17-26(29-19-36(21(2)39)31-14-8-5-11-24(29)31)34-33(25)27-12-6-9-15-32(27)37(34)22(3)40/h4-15,18-19,25-26H,16-17H2,1-3H3/t25-,26+/m1/s1 |
| InChIKey | MQLLMOHGZIBOOB-FTJBHMTQSA-N |
| XLogP | 7.59 |
| TPSA | 66.00 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 40 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 527.62 |
| LogP ≤ 5 | 7.59 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 127038395 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.